Skip to main content
Hannah N. Imlay
No Rating Available
(Learn About Our Rating System)

Hannah N. Imlay, MD, MS

Languages spoken: English
  • Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Infectious Disease)
  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Infectious Diseases
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Infectious Disease)

    Education history

    Graduate Training Epidemiology - University of Washington School of Public Health M.Sc.
    Fellowship Infectious Diseases - University of Washington Fellow
    Residency Internal Medicine - University of Michigan Medical School Resident
    Internship Internal Medicine - University of Michigan Medical School Intern
    Professional Medical Medicine - Northwestern University Feinberg School of Medicine M.D.
    Undergraduate Chemistry & Molecular/Cellular Biology - University of Illinois at Urbana–Champaign B.S.

    Selected Publications

    Journal Article

    1. Imlay H, Greenlee SB, Tritle BJ, Fino NF, Spivak ES (2024). In-person prospective audit and feedback on an oncology ward: development of an immunocompromised antimicrobial stewardship program. Antimicrob Steward Healthc Epidemiol, 4(1), e173. (Read full article)
    2. Yamauchi J, Raghavan D, Imlay H, Jweehan D, Oygen S, Marineci S, Remport A, Hall IE, Molnar MZ (2024). Deceased Organ Donor HTLV Screening Practices Postelimination of Universal Screening in the United States. Transplant Direct, 10(10), e1707. (Read full article)
    3. Imlay H, Gnann JW Jr, Rooney J, Peddi VR, Wiseman AC, Josephson MA, Kew C, Young JH, Adey DB, Samaniego-Picota M, Whitley RJ, Limaye AP (2024). A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy. Transpl Infect Dis, e14367. (Read full article)
    4. Imlay H, Thorpe A, Vaughn VM (2024). When antimicrobial stewardship begins with microbiological test requests: the case of asymptomatic bacteriuria. Curr Opin Infect Dis, 37(6), 565-572. (Read full article)
    5. Hosseini-Moghaddam SM, Kothari S, Humar A, Albasata H, Yetmar ZA, Razonable RR, Neofytos D, DAsaro M, Boggian K, Hirzel C, Khanna N, Manuel O, Mueller NJ, Imlay H, Kabbani D, Tyagi V, Smibert OC, Nasra M, Fontana L, Obeid KM, Apostolopoulou A, Zhang SX, Permpalung N, Alhatimi H, Silverman MS, Guo H, Rogers BA, MacKenzie E, Pisano J, Gioia F, Rapi L, Prasad GVR, Banegas M, Alonso CD, Doss K, Rakita RM, Fishman JA (2023). Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: A multicenter cohort, 2015-2020. Am J Transplant, 24(4), 653-668. (Read full article)
    6. Earl A, Greenlee S, Fong K, Imlay H, Spivak ES (2023). Positivity of repeat nasal MRSA PCR screening: a single-center experience. Antimicrob Steward Healthc Epidemiol, 3(1), e226. (Read full article)
    7. Yamauchi J, Azhar A, Hall IE, Bhalla A, Potluri VS, Tanriover B, Gupta G, Imlay H, Truax C, Balaraman V, Raghavan D, Zimmerman M, Campsen J, Rofaiel G, Baker T, Molnar MZ (2023). Comparison of Short-Term Outcomes in Kidney Transplant Recipients from SARS-CoV-2-Infected versus Noninfected Deceased Donors. Clin J Am Soc Nephrol, 18(11), 1466-1475. (Read full article)
    8. Wychera C, Imlay HN, Duke ER, Faino A, Li-Huang M, Stevens-Ayers T, Davis C, Lange-Sperandio B, Mallhi KK, Hill JA, Boeckh M, Englund JA, Hingorani S (2022). BK Viremia and Changes in Estimated Glomerular Filtration Rate in Children and Young Adults after Hematopoietic Cell Transplantation. Transplant Cell Ther, 29(3), 187.e1-187.e8. (Read full article)
    9. Imlay H, Limaye AP (2023). Authors' Reply. Transplantation, 107(3), e83. (Read full article)
    10. Imlay H, Wagener MM, Vutien P, Perkins J, Singh N, Limaye AP (2022). Increasing Proportion of High-risk Cytomegalovirus Donor-Positive/Recipient-Negative Serostatus in Solid Organ Transplant Recipients. Transplantation. (Read full article)
    11. Imlay H, Hodowanec AC, Komatsu TE, ORear J, Pikis A, Limaye AP (2022). Reply to Author. Clin Infect Dis, 75, 2047-2048. (Read full article)
    12. Imlay H, Baum P, Brennan DC, Hanson KE, Hodges MR, Hodowanec AC, Komatsu TE, Ljungman P, Miller V, Natori Y, Nickeleit V, ORear J, Pikis A, Randhawa PS, Sawinski D, Singh HK, Westman G, Limaye AP, BK Disease Definitions Working Group of the Transplantation Associated Virus Infection Forum with the Forum for Collaborative Research (2022). Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clin Infect Dis, 75, 1210-1216. (Read full article)
    13. Hannah Imlay and Ajit P Limaye (2022). Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections. UpToDate.
    14. Vutien P, Perkins J, Biggins SW, Reyes J, Imlay H, Limaye AP (2021). Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. Liver Transpl, 27(9), 1302-1311. (Read full article)
    15. Imlay HN, Kaul DR (2020). Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. Clin Infect Dis, 73(1), 156-160. (Read full article)
    16. Imlay H, Dasgupta S, Boeckh M, Stapleton RD, Rubenfeld GD, Chen Y, Limaye AP (2020). Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. J Infect Dis, 223(12), 2108-2112. (Read full article)
    17. Fox ER, Shah M, Vinik R, Brown S, Buckel W, Webb B, Zarndt J, Evans M, Mesdaghi P, Imlay HN, Spivak ES (2021). Developing statewide remdesivir use criteria. Am J Health Syst Pharm, 78(8), 732-735. (Read full article)
    18. Imlay H, Krantz EM, Stohs EJ, Lan KF, Zier J, Kim HN, Rakita RM, Limaye AP, Wald A, Pergam SA, Liu C (2019). Reported β-Lactam and Other Antibiotic Allergies in Solid Organ and Hematopoietic Cell Transplant Recipients. Clin Infect Dis, 71(7), 1587-1594. (Read full article)
    19. Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP (2020). Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients. Transpl Infect Dis, 22(3), e13255. (Read full article)
    20. Imlay H, Limaye AP (2020). Current Understanding of Cytomegalovirus Reactivation in Critical Illness. J Infect Dis, 221(Suppl 1), S94-S102. (Read full article)
    21. Imlay H, Xie H, Leisenring WM, Duke ER, Kimball LE, Huang ML, Pergam SA, Hill JA, Jerome KR, Milano F, Nichols WG, Pang PS, Hirsch HH, Limaye AP, Boeckh M (2019). Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Blood Adv, 4(4), 617-628. (Read full article)
    22. Ulrich RJ, Bott J, Imlay H, Lopez K, Cinti S, Rao K (2019). Clostridioides difficile Enteritis in Patients Following Total Colectomy-a Rare but Genuine Clinical Entity. Open Forum Infect Dis, 6(11), ofz409. (Read full article)
    23. Steinbrink J, Imlay H, Rao K, Riddell J 4th (2019). Identifying causes of persistent HIV viremia in adult patients at an academic medical center. SAGE Open Med, 7, 2050312119851006. (Read full article)
    24. Imlay H, Whitaker K, Fisher CE, Limaye AP (2018). Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis, 20(4), e12928. (Read full article)
    25. Imlay H, Kaul D, Rao K (2016). Risk factors for Clostridium difficile infection in HIV-infected patients. SAGE Open Med, 4, 2050312116684295. (Read full article)

    Review

    1. Hand J, Imlay H (2023). Antimicrobial Stewardship in Immunocompromised Patients: Current State and Future Opportunities. [Review]. Infect Dis Clin North Am, 37(4), 823-851. (Read full article)
    2. Imlay H, Seibert AM, Hanson KE (2023). Pathogen-agnostic immune biomarkers that predict infection after solid organ transplantation. [Review]. Transpl Infect Dis, e14020. (Read full article)
    3. Imlay H, Spellberg B (2022). Shorter is better: The case for short antibiotic courses for common infections in solid organ transplant recipients. [Review]. Transpl Infect Dis, 24(5), e13896. (Read full article)
    4. Imlay H, Laundy NC, Forrest GN, Slavin MA (2022). Shorter antibiotic courses in the immunocompromised: the impossible dream? [Review]. Clin Microbiol Infect. (Read full article)

    Book Chapter

    1. Hannah Imlay and Kimberly E Hanson (). Infection Surveillance Prior to Transplantation. In Amy Leber (Ed.), Clinical Microbiology Procedures Handbook.

    Editorial

    1. Imlay H, Hanson KE (2023). Updates in Prevention, Diagnosis, and Management of Infections Among Solid Organ Transplant Recipients. Infect Dis Clin North Am, 37(3), xiii-xv. (Read full article)

    Letter

    1. Molnar MZ, Hall IE, Raghavan D, Shihab F, Imlay H, Hanson KE, Gomez CA, Campsen J, Kim R, Baker N, Rofaiel G (2021). Kidney transplantation from SARS-CoV-2-positive deceased donor. [Letter to the editor]. Am J Transplant, 22(4), 1280-1282. (Read full article)
    2. Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP (2021). Examining valganciclovir prophylaxis duration among high-risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort. [Letter to the editor]. Transpl Infect Dis, 23, e13581. (Read full article)

    Other

    1. Heeren JR, Imlay HN, Estes RE, Tinsley NA, Steffey KL, Gray ME (2008). Evaluation of foliar-applied insecticides to control pests of alfalfa in Illinois. On Target: 2008 Report (Section 9, pp. 30-2). Department of Crop Sciences, University of Illinois.